Travere Therapeutics Past Earnings Performance
Past criteria checks 0/6
Travere Therapeutics's earnings have been declining at an average annual rate of -25.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 1.4% per year.
Key information
-25.4%
Earnings growth rate
-12.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 1.4% |
| Return on equity | -187.4% |
| Net Margin | -259.1% |
| Next Earnings Update | 06 May 2024 |
Recent past performance updates
Recent updates
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Oct 07Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
Aug 30Travere: Setback Presents Cautious Opportunity
Jul 18Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Jul 09Revenue & Expenses BreakdownBeta
How Travere Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 145 | -376 | 266 | 0 |
| 30 Sep 23 | 232 | -320 | 282 | 0 |
| 30 Jun 23 | 223 | -315 | 266 | 0 |
| 31 Mar 23 | 221 | -289 | 246 | 0 |
| 31 Dec 22 | 109 | -331 | 198 | 0 |
| 30 Sep 22 | 137 | -297 | 183 | 0 |
| 30 Jun 22 | 178 | -249 | 166 | 0 |
| 31 Mar 22 | 229 | -202 | 160 | 0 |
| 31 Dec 21 | 132 | -217 | 126 | 0 |
| 30 Sep 21 | 221 | -250 | 144 | -93 |
| 30 Jun 21 | 204 | -237 | 139 | -61 |
| 31 Mar 21 | 198 | -224 | 139 | -30 |
| 31 Dec 20 | 198 | -169 | 136 | 0 |
| 30 Sep 20 | 194 | -78 | 128 | 130 |
| 30 Jun 20 | 187 | -92 | 125 | 131 |
| 31 Mar 20 | 184 | -105 | 129 | 138 |
| 31 Dec 19 | 175 | -146 | 129 | 0 |
| 30 Sep 19 | 172 | -124 | 127 | 137 |
| 30 Jun 19 | 169 | -142 | 124 | 136 |
| 31 Mar 19 | 165 | -125 | 110 | 133 |
| 31 Dec 18 | 164 | -103 | 104 | 124 |
| 30 Sep 18 | 163 | -113 | 104 | 111 |
| 30 Jun 18 | 162 | -76 | 101 | 97 |
| 31 Mar 18 | 160 | -67 | 105 | 82 |
| 31 Dec 17 | 155 | -60 | 101 | 78 |
| 30 Sep 17 | 150 | -51 | 101 | 79 |
| 30 Jun 17 | 144 | -70 | 102 | 79 |
| 31 Mar 17 | 138 | -70 | 96 | 77 |
| 31 Dec 16 | 134 | -48 | 92 | 71 |
| 30 Sep 16 | 127 | -42 | 88 | 66 |
| 30 Jun 16 | 121 | 101 | 87 | 62 |
| 31 Mar 16 | 112 | 89 | 84 | 55 |
| 31 Dec 15 | 100 | 117 | 80 | 50 |
| 30 Sep 15 | 84 | 91 | 69 | 50 |
| 30 Jun 15 | 64 | -33 | 64 | 48 |
| 31 Mar 15 | 46 | 4 | 53 | 51 |
| 31 Dec 14 | 28 | -111 | 59 | 48 |
| 30 Sep 14 | 14 | -95 | 49 | 38 |
| 30 Jun 14 | 6 | -89 | 36 | 27 |
| 31 Mar 14 | 0 | -105 | 31 | 14 |
| 31 Dec 13 | 0 | -35 | 18 | 7 |
| 30 Sep 13 | 0 | -36 | 24 | 2 |
Quality Earnings: TVTX is currently unprofitable.
Growing Profit Margin: TVTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TVTX is unprofitable, and losses have increased over the past 5 years at a rate of 25.4% per year.
Accelerating Growth: Unable to compare TVTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TVTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: TVTX has a negative Return on Equity (-187.41%), as it is currently unprofitable.